ArticleFrontiers in oncology2026
Ultrasound - based deep learning radiomics nomogram for noninvasive prediction of p53 mutation status in hepatocellular carcinoma: a variational autoencoder based development and validation study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Accurate preoperative assessment of p53 mutation status in hepatocellular carcinoma (HCC) is critical for prognostic stratification and personalized treatment planning. Conventional radiomics approaches often suffer from feature redundancy and limited generalization. This study aimed to develop and validate a noninvasive ultrasound-based radiomics nomogram integrating variational autoencoder (VAE)-derived deep features to predict p53 expression status, addressing these limitations. Methods: A retrospective cohort of 172 patients with pathologically confirmed HCC (training cohort: n=120, validation cohort: n=52) who underwent preoperative two-dimensional ultrasound images and had available p53 immunohistochemistry (IHC) results was analyzed. ultrasound images were segmented, and radiomic features were extracted from them. A VAE network was employed to reduce feature dimensionality and extract high-level malignant risk scores. These scores were integrated with clinical variables (Alpha-Fetoprotein [AFP] levels, Microvascular Invasion [MVI] status, and Edmondson-Steiner (E-S) grade) to construct a predictive nomogram. Model performance was evaluated using receiver operating characteristic (ROC) analysis (area under the curve [AUC]), calibration curves, and decision curve analysis (DCA). Results: The VAE-integrated nomogram achieved robust predictive performance, with an AUC of 0.925 (95% CI: 0.881-0.969) in the training cohort and 0.820 (95% CI: 0.699-0.942) in the validation cohort. Calibration curves demonstrated close alignment between predicted and observed probabilities, and decision curve analysis confirmed clinical utility across a broad threshold probability range. Key clinical benefits included noninvasive assessment of p53 mutation and enhanced interpretability through combined deep learning and clinical parameters. Conclusion: This VAE-based radiomics framework effectively combines deep feature representation with clinical variables, providing a reliable tool for noninvasive preoperative evaluation of HCC p53 mutation. The model shows promise for optimizing surgical decision-making and personalized prognostic strategies in HCC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.